Patent ID: 9433664
Filing Date: 2016-09-06
CPC Classification: A61K,A61P

Claim Text:
1. A method of normalizing impaired haemostasis associated with dilutional coagulopathy in a mammal in need thereof comprising administering a clotting factor treatment selected from the group consisting of: (1) recombinant human FII (rhFII), (2) a combination of rhFII and recombinant human FVIIa (rhVIIa), (3) a combination of rhFII, rhVIIa, and recombinant human FX (rhFX), (4) fibrinogen and a combination of rhFII, rhFVIIa, and rhFX, (5) fibrinogen and rhFII, and (6) fibrinogen and a combination of rhFII and rhVIIa, wherein administration of said clotting factor treatment is performed without co-administration of any other coagulation factors selected from human coagulation factors FV-FXIII.